Recent phase 3 data with the glucagon-like peptide-1 receptor agonist semaglutide in adults with NASH and fibrosis have demonstrated substantial improvements in steatohepatitis and weight reduction, highlighting the potential of incretin-based therapies in this field. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatohepatitis.